BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 10626173)

  • 1. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
    Tromm A; Griga T; May B
    Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
    Gibson PR; Fixa B; Pekárková B; Bátovský M; Radford-Smith G; Tibitanzl J; Gabalec L; Florin TH; Greinwald R
    Aliment Pharmacol Ther; 2006 Apr; 23(7):1017-26. PubMed ID: 16573804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
    Prakash A; Markham A
    Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.
    Gross V; Andus T; Fischbach W; Weber A; Gierend M; Hartmann F; Schölmerich J
    Z Gastroenterol; 1995 Oct; 33(10):581-4. PubMed ID: 7502549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug treatment of Crohn's disease].
    van Deventer SJ; Tytgat GN
    Ned Tijdschr Geneeskd; 1998 May; 142(21):1191-5. PubMed ID: 9627451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anastomotic configuration and mucosal 5-aminosalicyclic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Gruppo Italiano per lo Studio del Colon e del Retto.
    Frieri G; Pimpo MT; Palumbo G; Tonelli F; Annese V; Sturniolo GC; Andreoli A; Comberlato M; Corrao G; Caprilli R
    Am J Gastroenterol; 2000 Jun; 95(6):1486-90. PubMed ID: 10894584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
    Robinson MG
    Gastroenterol Clin North Am; 1989 Mar; 18(1):43-50. PubMed ID: 2646221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical therapy to reduce postoperative Crohn's disease recurrence.
    Achkar JP; Hanauer SB
    Am J Gastroenterol; 2000 May; 95(5):1139-46. PubMed ID: 10811318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
    Christensen LA; Jacobsen BA
    Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
    Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience.
    Bresci G; Parisi G; Banti S
    Int J Clin Pharmacol Res; 1994; 14(4):133-8. PubMed ID: 7607786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE; Schraa CC
    Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.
    Marakhouski Y; Fixa B; Holomán J; Hulek P; Lukas M; Bátovský M; Rumyantsev VG; Grigoryeva G; Stolte M; Vieth M; Greinwald R;
    Aliment Pharmacol Ther; 2005 Jan; 21(2):133-40. PubMed ID: 15679762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In favour of prophylactic treatment for post-operative recurrence in Crohn's disease.
    Caprilli R; Taddei G; Viscido A
    Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):219-25. PubMed ID: 9675663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.